JP2013506696A - 心不全の予防又は処置の方法 - Google Patents

心不全の予防又は処置の方法 Download PDF

Info

Publication number
JP2013506696A
JP2013506696A JP2012532388A JP2012532388A JP2013506696A JP 2013506696 A JP2013506696 A JP 2013506696A JP 2012532388 A JP2012532388 A JP 2012532388A JP 2012532388 A JP2012532388 A JP 2012532388A JP 2013506696 A JP2013506696 A JP 2013506696A
Authority
JP
Japan
Prior art keywords
peptide
phe
subject
heart failure
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012532388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506696A5 (enExample
Inventor
ピーター エス ラヴィノヴィッチ
ダオ−フー ダイ
ヘーゼル エイチ ツェト
Original Assignee
コーネル ユニヴァーシティー
ユニヴァーシティ オブ ワシントン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, ユニヴァーシティ オブ ワシントン filed Critical コーネル ユニヴァーシティー
Publication of JP2013506696A publication Critical patent/JP2013506696A/ja
Publication of JP2013506696A5 publication Critical patent/JP2013506696A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2012532388A 2009-10-05 2010-10-04 心不全の予防又は処置の方法 Pending JP2013506696A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24868109P 2009-10-05 2009-10-05
US61/248,681 2009-10-05
US28948309P 2009-12-23 2009-12-23
US61/289,483 2009-12-23
PCT/US2010/051329 WO2011044044A1 (en) 2009-10-05 2010-10-04 Methods for the prevention or treatment of heart failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015050464A Division JP2015163609A (ja) 2009-10-05 2015-03-13 心不全の予防又は処置の方法

Publications (2)

Publication Number Publication Date
JP2013506696A true JP2013506696A (ja) 2013-02-28
JP2013506696A5 JP2013506696A5 (enExample) 2013-11-21

Family

ID=43823652

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2012532388A Pending JP2013506696A (ja) 2009-10-05 2010-10-04 心不全の予防又は処置の方法
JP2015050464A Pending JP2015163609A (ja) 2009-10-05 2015-03-13 心不全の予防又は処置の方法
JP2016156631A Active JP6429835B2 (ja) 2009-10-05 2016-08-09 心不全の予防又は処置の方法
JP2018165223A Pending JP2018203764A (ja) 2009-10-05 2018-09-04 心不全の予防又は処置の方法
JP2020030241A Active JP7017762B2 (ja) 2009-10-05 2020-02-26 心不全の予防又は処置の方法
JP2022006917A Active JP7382607B2 (ja) 2009-10-05 2022-01-20 心不全の予防又は処置の方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2015050464A Pending JP2015163609A (ja) 2009-10-05 2015-03-13 心不全の予防又は処置の方法
JP2016156631A Active JP6429835B2 (ja) 2009-10-05 2016-08-09 心不全の予防又は処置の方法
JP2018165223A Pending JP2018203764A (ja) 2009-10-05 2018-09-04 心不全の予防又は処置の方法
JP2020030241A Active JP7017762B2 (ja) 2009-10-05 2020-02-26 心不全の予防又は処置の方法
JP2022006917A Active JP7382607B2 (ja) 2009-10-05 2022-01-20 心不全の予防又は処置の方法

Country Status (7)

Country Link
US (7) US20110082084A1 (enExample)
EP (5) EP2944317A1 (enExample)
JP (6) JP2013506696A (enExample)
CN (2) CN103845724A (enExample)
CA (1) CA2776581C (enExample)
HK (1) HK1217293A1 (enExample)
WO (1) WO2011044044A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9306796B1 (en) 2008-03-18 2016-04-05 Mcafee, Inc. System, method, and computer program product for dynamically configuring a virtual environment for identifying unwanted data
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
EP4005582A1 (en) * 2012-10-22 2022-06-01 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
JP6518197B2 (ja) * 2013-03-01 2019-05-22 ステルス バイオセラピューティックス コープ バース症候群の予防または治療のための方法及び組成物
CN116474071A (zh) * 2013-03-01 2023-07-25 康德生物医疗有限公司 治疗线粒体疾病的方法
CA2912386A1 (en) * 2013-05-14 2014-11-20 Stealth Biotherapeutics Corp Methods for the prevention or treatment of left ventricular remodeling
US20160095867A1 (en) * 2013-05-28 2016-04-07 Dana-Farber Cancer Institute, Inc. Bet inhibition therapy for heart disease
US10047395B2 (en) 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US20160166633A1 (en) * 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
WO2016004441A1 (en) * 2014-07-03 2016-01-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of acute myocardial infarction injury
US10368774B2 (en) * 2015-07-30 2019-08-06 Medtronic, Inc. Absolute intrathoracic impedance based scheme to stratify patients for risk of a heart failure event
CA3010599C (en) * 2016-01-06 2025-05-20 Stealth Biotherapeutics Inc. METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
WO2017151886A1 (en) * 2016-03-02 2017-09-08 Stealth Biotherapeutics Corp Methods and compositions for the treatment and prevention of pulmonary arterial hypertension
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018005990A2 (en) * 2016-07-01 2018-01-04 Marshall University Research Corporation Compositions and methods for treating uremic cardiomyopathy
EP3612178A4 (en) 2017-04-21 2021-01-13 Northeast Ohio Medical University VASODILATERS FOR THE TREATMENT OF HEART FAILURE
WO2020118035A1 (en) * 2018-12-06 2020-06-11 Stealth Biotherapeutics Corp Methods and compositions for the treatment of sengers syndrome
CN112111003B (zh) * 2019-06-20 2022-02-11 中国农业大学 含有me序列的一类新型抑制血小板聚集和抗血栓形成寡肽
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
US20230256047A1 (en) * 2020-06-17 2023-08-17 Stealth Biotherapeutics Inc. Methods and compositions for the treatment of muscular dystrophy
GB2614162B (en) 2020-09-09 2024-11-06 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN117384253A (zh) * 2023-08-28 2024-01-12 南京医科大学 一类肽及其衍生物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248808A1 (en) * 2003-02-04 2004-12-09 Szeto Hazel H. Methods for preventing mitochondrial permeability transition
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4732898A (en) * 1986-04-29 1988-03-22 Warner-Lambert Company 2-(2-aryl-2-oxoalkylidene) analogs of-3,5-pyridinedicarboxylic acid dialkyl esters useful for treatment of cardiovascular disorders
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
ATE136905T1 (de) * 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5670617A (en) * 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) * 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU7856600A (en) * 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
IT1318370B1 (it) * 2000-12-21 2003-08-25 Tonino Bombardini Metodo e dispositivo per la diagnosi e la terapia dello scompensocardiaco cronico.
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
WO2003029428A2 (en) * 2001-10-01 2003-04-10 Vanderbilt University Use of calmodulin kinase ii inhibitors to treat myocardial dysfunction in structural heart disease
US7776925B2 (en) * 2002-03-06 2010-08-17 Duke University Reversing, postponing or preventing the occurrence of GTN tolerance and/or generation of reactive oxygen species from mitochondria
ES2694574T3 (es) * 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA2851972C (en) * 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
AU2006292352B2 (en) * 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
US20110082084A1 (en) 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
WO2011151359A1 (en) * 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248808A1 (en) * 2003-02-04 2004-12-09 Szeto Hazel H. Methods for preventing mitochondrial permeability transition
WO2009100363A2 (en) * 2008-02-07 2009-08-13 Cornell University Methods for preventing or treating insulin resistance

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014038872; Ｊａｎｇｈｙｕｎ　Ｃｈｏ: Ｃｏｒｏｎａｒｙ　Ａｒｔｅｒｙ　Ｄｉｓｅａｓｅ Ｖｏｌ．１８，　Ｎｏ．３, 2007, ｐｐ．２１５-２２０ *

Also Published As

Publication number Publication date
JP2016190876A (ja) 2016-11-10
US20110082084A1 (en) 2011-04-07
US20180236025A1 (en) 2018-08-23
CN103845724A (zh) 2014-06-11
EP2944317A1 (en) 2015-11-18
EP2485749A1 (en) 2012-08-15
JP7382607B2 (ja) 2023-11-17
JP2022046811A (ja) 2022-03-23
US20230285499A1 (en) 2023-09-14
EP3120860B1 (en) 2019-06-26
EP3603658A1 (en) 2020-02-05
JP2020097627A (ja) 2020-06-25
JP2018203764A (ja) 2018-12-27
CN102711785A (zh) 2012-10-03
US20210187056A1 (en) 2021-06-24
JP2015163609A (ja) 2015-09-10
US20140100166A1 (en) 2014-04-10
EP3120860A1 (en) 2017-01-25
US20200188470A1 (en) 2020-06-18
EP3603658B1 (en) 2025-01-08
EP2764871A1 (en) 2014-08-13
WO2011044044A1 (en) 2011-04-14
CA2776581A1 (en) 2011-04-14
US12102659B2 (en) 2024-10-01
US20160106800A1 (en) 2016-04-21
JP7017762B2 (ja) 2022-02-09
US11534476B2 (en) 2022-12-27
JP6429835B2 (ja) 2018-11-28
HK1217293A1 (en) 2017-01-06
EP2485749A4 (en) 2013-07-24
CA2776581C (en) 2020-12-15

Similar Documents

Publication Publication Date Title
JP7382607B2 (ja) 心不全の予防又は処置の方法
US20180104304A1 (en) Methods for preventing or treating metabolic syndrome
US10525098B2 (en) Methods for the regulation of matrix metalloproteinase expression
JP2019052157A (ja) 左室リモデリングの予防または治療のための方法
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction
HK1233532B (en) Methods for the prevention or treatment of cardiac fibrosis
HK1233532A1 (en) Methods for the prevention or treatment of cardiac fibrosis
HK1176561A (en) Methods for the prevention or treatment of heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141216

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141224

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150706